Expression of mediated P-glycoprotein multidrug resistance related to Tc-99m MIBI scintimammography results

Cancer Lett. 2000 May 29;153(1-2):95-100. doi: 10.1016/s0304-3835(00)00356-6.


We prospectively studied a total of 24 patients with breast cancer to evaluate the relationship between the degree of accumulation of technetium-99m sestamibi (Tc-99m MIBI) and p-glycoprotein (Pgp) expression in tumor tissues. All 24 patients underwent Tc-99m MIBI scintimammography before surgery or biopsy. Immunohistochemical studies were performed on multiple non-consecutive sections of the same tumor using a Pgp specific monoclonal antibody, JSB-1. Planar images were started 10 min after injection of Tc-99m MIBI. Tumor to background (T/B) ratios calculated from the planar images were correlated with Pgp expression as determined by immunohistochemical studies. The T/B ratios were significantly lower for tumors in eight patients with positive Pgp expression (Group 1) than in 16 patients with negative expression (Group 2) (1.40+/-0.11 and 2.76+/-0.60, P<0. 05). Our data confirmed that Tc-99m MIBI scintimammography is useful for determination of the presence of multidrug resistance due to Pgp expression in patients with breast cancer.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / biosynthesis*
  • Adult
  • Biological Transport
  • Breast Neoplasms / metabolism*
  • Drug Resistance, Multiple / physiology*
  • Female
  • Humans
  • Immunohistochemistry
  • Middle Aged
  • Prospective Studies
  • Radiopharmaceuticals / pharmacokinetics
  • Technetium Tc 99m Sestamibi / pharmacokinetics*


  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Radiopharmaceuticals
  • Technetium Tc 99m Sestamibi